CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 10-Q Report Quarterly Report
- 8-K Event Results of operations · Executive or director change
- 4 Planned sale Chief Scientific Officer sold 63,606 shares at an average $28.25 ($1,796,676)
- 144 Insider Sale of Securities
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- SC 13G Stake Amended Statement of Ownership
- 8-K Event Material agreement · Unregistered share sale · Bylaws or fiscal year change · Regulation FD disclosure · Other events
- 3 Insider Initial Statement of Ownership
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Grant or award Chief Business Officer acquired 37,500 shares (grant or award)
- 4 Grant or award President and CEO acquired 160,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 50,000 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 62,500 shares (grant or award)
Page 10 of 24 · 471 filings